AC Immune

AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. 

The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in a Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. 

In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovered preclinical stage molecules targeting a range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA is a Swiss biopharmaceutical company that was founded in 2003 by Professors Andrea Pfeifer, Remo Rohs, and Professor Jean-Claude Reubi. The company is focused on the development of novel diagnostics and therapeutics for the prevention, diagnosis, and treatment of neurodegenerative diseases.

The company's founders had the ambition to develop a platform technology that could be used to design and create novel, specific antibodies and small molecules to fight diseases like Alzheimer’s and Parkinson’s, as well as other age-related diseases. AC Immune was founded with the mission to develop new treatments, both preventive and curative, to combat these complex diseases.

Since its inception, AC Immune has worked with world-renowned scientists, clinicians, and venture capital investors to develop innovative products and services. The company has raised more than $250 million in venture capital and has established several strategic partnerships with leading global biopharmaceutical companies.

AC Immune has developed a broad pipeline of products, including diagnostic and therapeutic antibodies, small molecules, and vaccines. In addition, the company has developed a novel platform technology, Morphomer, which enables the design and production of monoclonal antibodies and small molecules with enhanced specificity and potency.

To date, AC Immune has successfully completed multiple clinical trials, and its products are currently in Phase III clinical trials. The company is also actively engaged in collaborations with leading global pharmaceutical and biotechnology companies, as well as academic and research institutions.

AC Immune is committed to making a difference in the lives of patients suffering from neurodegenerative diseases by developing innovative treatments and diagnostics. The company is well-positioned to become a leader in the field of neurodegenerative disease research and development.

“Our mission is to empower patients by providing access to innovative and effective treatments through the development and delivery of precision healthcare products to fight neurodegenerative diseases.”

“Our vision is to become a leader in the development of precision healthcare solutions to improve the lives of patients with neurodegenerative diseases.”